Shares of Bristol Myers Squibb Co. BMY advanced 1.90% to $60.02 Friday, on what proved to be an all-around dismal trading ...

Bristol-Myers Squibb (NYSE:BMY) recently announced positive topline results from its Phase 3 trials for Sotyktu, generating ...

Healthcare stocks have been out of vogue with investors since late 2022. Myriad reasons underlie the negative sentiment ...

BMY has enjoyed robust capital appreciation over the past few months, significantly aided by the ongoing market rotation to ...

We recently published a list of 10 Firms End Friday Strong; 3 Reach All-Time Highs. In this article, we are going to take a ...

Shares of Bristol Myers Squibb Co. slid 3.05% to $59.19 Tuesday, on what proved to be an all-around favorable trading session ...

Bristol-Myers Squibb awarded its CEO nearly $19 million in compensation for 2024, following a challenging year for the ...

Bristol Myers (BMY) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended approval ...

Bristol Myers (BMY) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended approval ...

Bristol Myers Squibb said a key European regulatory committee is backing a formulation of its blockbuster cancer drug Opdivo that can be injected under the skin.

Three stocks that are trading at attractive valuations right now that you may not want to overlook are Bristol Myers Squibb ( ...

Bristol-Myers Squibb (NYSE:BMY – Get Free Report) has been assigned a consensus rating of “Hold” from the nineteen brokerages that are covering the company, Marketbeat.com reports. Two research ...